PMID- 32085772 OWN - NLM STAT- MEDLINE DCOM- 20200831 LR - 20200831 IS - 1475-2840 (Electronic) IS - 1475-2840 (Linking) VI - 19 IP - 1 DP - 2020 Feb 21 TI - The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. PG - 23 LID - 10.1186/s12933-020-0989-8 [doi] LID - 23 AB - BACKGROUND: Many studies have reported the predictive value of the atherogenic index of plasma (AIP) in the progression of atherosclerosis and the prognosis of percutaneous coronary intervention (PCI). However, the utility of the AIP for prediction is unknown after PCI among type 2 diabetes mellitus (T2DM). METHODS: 2356 patients with T2DM who underwent PCI were enrolled and followed up for 4 years. The primary outcome was major cardiovascular and cerebrovascular adverse events (MACCEs), considered to be a combination of cardiogenic death, myocardial infarction, repeated revascularization, and stroke. Secondary endpoints included all-cause mortality, target vessel revascularization (TVR), and non-target vessel revascularization (non-TVR). Multivariate Cox proportional hazards regression modelling found that the AIP was correlated with prognosis and verified by multiple models. According to the optimal cut-off point of the ROC curve, the population was divided into high/low-AIP groups. A total of 821 pairs were successfully matched using propensity score matching. Then, survival analysis was performed on both groups. RESULTS: The overall incidence of MACCEs was 20.50% during a median of 47.50 months of follow-up. The multivariate Cox proportional hazards regression analysis before matching suggested that the AIP was an independent risk factor for the prognosis of T2DM after PCI (hazard ratio [HR] 1.528, 95% CI 1.100-2.123, P = 0.011). According to the survival analysis of the matched population, the prognosis of the high AIP group was significantly worse than that of the low AIP group (HR (95% CI) 1.614 (1.303-2.001), P < 0.001), and the difference was mainly caused by repeat revascularization. The low-density lipoprotein-cholesterol (LDL-C) level did not affect the prognosis of patients with T2DM (P = 0.169), and the effect of the AIP on prognosis was also not affected by LDL-C level (P < 0.001). CONCLUSIONS: The AIP, a comprehensive index of lipid management in patients with T2DM, affects prognosis after PCI. The prognosis of diabetic patients with high levels of the AIP included more MACCEs and was not affected by LDL-C levels. It is recommended to monitor the AIP for lipid management in diabetic patients after PCI and ensure that the AIP is not higher than 0.318. Trial registration This is an observational cohort study that does not involve interventions. So we didn't register. We guarantee that the research is authentic and reliable, and hope that your journal can give us a chance. FAU - Qin, Zheng AU - Qin Z AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Zhou, Kuo AU - Zhou K AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Li, Yueping AU - Li Y AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Cheng, Wanjun AU - Cheng W AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Wang, Zhijian AU - Wang Z AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Wang, Jianlong AU - Wang J AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Gao, Fei AU - Gao F AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Yang, Lixia AU - Yang L AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Xu, Yingkai AU - Xu Y AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Wu, Yafeng AU - Wu Y AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - He, Hua AU - He H AD - Department of Emergency Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - Zhou, Yujie AU - Zhou Y AUID- ORCID: 0000-0002-9545-1984 AD - Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotlic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. azzyj12@163.com. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20200221 PL - England TA - Cardiovasc Diabetol JT - Cardiovascular diabetology JID - 101147637 RN - 0 (Biomarkers) RN - 0 (Blood Glucose) RN - 0 (Lipids) SB - IM MH - Aged MH - Beijing/epidemiology MH - Biomarkers/blood MH - Blood Glucose/*metabolism MH - Coronary Artery Disease/blood/diagnostic imaging/mortality/*therapy MH - Diabetes Mellitus, Type 2/*blood/diagnosis/mortality MH - Dyslipidemias/*blood/diagnosis/mortality MH - Female MH - Humans MH - Incidence MH - Lipids/*blood MH - Male MH - Middle Aged MH - Myocardial Infarction/mortality MH - *Percutaneous Coronary Intervention/adverse effects/mortality MH - Risk Assessment MH - Risk Factors MH - Stroke/mortality MH - Time Factors MH - Treatment Outcome PMC - PMC7035714 OTO - NOTNLM OT - Atherogenic index of plasma OT - Major cardiovascular and cerebrovascular adverse events OT - Percutaneous coronary intervention OT - Type 2 diabetes mellitus COIS- The authors declare that they have no competing interests. EDAT- 2020/02/23 06:00 MHDA- 2020/09/01 06:00 PMCR- 2020/02/21 CRDT- 2020/02/23 06:00 PHST- 2019/12/01 00:00 [received] PHST- 2020/01/14 00:00 [accepted] PHST- 2020/02/23 06:00 [entrez] PHST- 2020/02/23 06:00 [pubmed] PHST- 2020/09/01 06:00 [medline] PHST- 2020/02/21 00:00 [pmc-release] AID - 10.1186/s12933-020-0989-8 [pii] AID - 989 [pii] AID - 10.1186/s12933-020-0989-8 [doi] PST - epublish SO - Cardiovasc Diabetol. 2020 Feb 21;19(1):23. doi: 10.1186/s12933-020-0989-8.